Reference
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
- Reck M, Rabe KF. Advanced non-small-cell lung cancer. N Engl J Med. 2017;377(20):1999.
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
- Li A, Cao W, Liu X, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020;146(7):1737–1749.
- Porta C, Paglino C, Mosca A. Targeting PI3K/akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
- Brown KK, Toker A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 2015;7:13.
- Ahlskog JK, Larsen BD, Achanta K, et al. ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO Rep. 2016;17(5):671–681.
- Yue X, Bai C, Xie D, et al. DNA-PKcs: a multi-faceted player in DNA damage response. Front Genet. 2020;11:607428.
- Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21(2):251–259.
- Xu N, Lao Y, Zhang Y, et al. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012; 2012:951724.
- Iksen Pothongsrisit S, Pongrakhananon V. Targeting the PI3K/AKT/mTOR signaling pathway in lung cancer: an update regarding potential drugs and natural products. Molecules. 2021;26(13):4100.
- Fròsina G, Profumo A, Marubbi D, et al. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat Oncol. 2018;13(1):76.
- Mukherjee B, Tomimatsu N, Amancherla K, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012;14(1):34–43.
- Calero R, Morchon E, Martinez-Argudo I, et al. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017; 406:1–411.
- Marcondes NA, Terra SR, Lasta CS, et al. Comparison of JC-1 and MitoTracker probes for mitochondrial viability assessment in stored canine platelet concentrates: a flow cytometry study. Cytometry A. 2019;95(2):214–218.
- Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
- Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37–50.
- Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332(2):237–248.
- Menolfi D, Zha S. ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion. Cell Biosci. 2020;10:8.
- Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189.
- Endo H, Inoue I, Masunaka K, et al. Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of bad. Biosci Biotechnol Biochem. 2020;84(12):2440–2447.
- Foote KM, Blades K, Cronin A, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013;56(5):2125–2138.
- Sabbah DA, Hajjo R, Bardaweel SK, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020). Expert Opin Ther Pat. 2021;31(10):877–892.
- Batool A, Majeed ST, Aashaq S, et al. Eukaryotic initiation factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin. Int J Biol Macromol. 2019;125:651–659.
- Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221–11229.
- Wan G, Liu Y, Zhu J, et al. SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway. Cell Signal. 2019;59:1–12.
- Enriquez-Rios V, Dumitrache LC, Downing SM, et al. DNA-PKcs, ATM, and ATR interplay maintains genome integrity during neurogenesis. J Neurosci. 2017;37(4):893–905.
- Arnoult N, Correia A, Ma J, et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature. 2017;549(7673):548–552.
- Reddy D, Kumavath R, Ghosh P, et al. Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways. Biomolecules. 2019;9(12):792.